Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Lilly's move comes as Zepbound seems to be building momentum ... reported the first signs of weaker growth for Wegovy. The new launch has caught the attention of President Joe Biden, who said ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

U.S. and China to pause most tariffs for 90 days, slash reciprocal rates. Amazon-backed Scale AI sets sights on Saudi ...